Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)
<p><strong>Background:</strong> Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy.</p> <p><strong>Methods:</strong> BCN01 trial was a phase I, open-label, non-r...
Main Authors: | Mothe, B, Manzardo, C, Sanchez-Bernabeu, A, Coll, P, Morón-López, S, Puertas, MC, Rosas-Umbert, M, Cobarsi, P, Escrig, R, Perez-Alvarez, N, Ruiz, I, Rovira, C, Meulbroek, M, Crook, A, Borthwick, N, Wee, EG, Yang, H, Miró, JM, Dorrell, L, Clotet, B, Martinez-Picado, J, Brander, C, Hanke, T, BCN 01 study group |
---|---|
Formato: | Journal article |
Publicado: |
Elsevier
2019
|
Títulos similares
-
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
por: Beatriz Mothe, et al.
Publicado: (2019-05-01) -
In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial
por: Rosás-Umbert, M, et al.
Publicado: (2020) -
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
por: Beatriz Mothe, et al.
Publicado: (2020-05-01) -
HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (Study BCN02)
por: Mothe, B, et al.
Publicado: (2020) -
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
por: Miriam Rosás-Umbert, et al.
Publicado: (2020-03-01)